High Risk Stocks To Buy 2017 ❲Exclusive | EDITION❳

: Aggressive investors also looked at high-yield dividend stocks such as AstraZeneca (AZN) and GameStop (GME) , which offered potential capital appreciation alongside dividends, though they carried elevated risk during market transitions. Key Market Drivers for 2017

For investors in 2017, the "high-risk, high-reward" segment of the market was defined by a strong rebound in energy, explosive breakthroughs in biotechnology, and the rising dominance of high-growth technology. While the broader market saw a lack of volatility, with the S&P 500 rising roughly 20% and the Nasdaq nearly 30%, these specific sectors offered triple-digit gains for those willing to stomach higher volatility. high risk stocks to buy 2017

: Nine of the top ten performing stocks of the year were in the biotech sector. Companies like Vertex Pharmaceuticals (VRTX) (up 97%) and Dynavax Technologies (DVAX) (up 373%) succeeded based on FDA approvals and breakthrough trial data. : Aggressive investors also looked at high-yield dividend

: The maker of Invisalign benefited from a near-monopoly on invisible braces, seeing a 131% increase as it expanded its training to thousands of dentists globally. : Nine of the top ten performing stocks

: Stocks like Freeport-McMoRan (FCX) and Cameco (CCJ) were considered high-risk due to volatile commodity prices. FCX, in particular, was viewed as a speculative "survival" play as it wrestled with high debt levels relative to cash flow.

: Despite a "chaotic news cycle," markets remained remarkably steady, allowing growth premiums to outperform value premiums significantly.

: Another biotech leader, Nektar returned 387% following positive news regarding its immuno-oncology and painkiller treatments.